grace capital Trims Stake in Edwards Lifesciences Corp (EW)

grace capital cut its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 11.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,870 shares of the medical research company’s stock after selling 1,708 shares during the quarter. Edwards Lifesciences accounts for 1.0% of grace capital’s portfolio, making the stock its 27th largest holding. grace capital’s holdings in Edwards Lifesciences were worth $2,124,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in EW. Sontag Advisory LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $26,000. Lindbrook Capital LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $27,000. Capital Financial Planning LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $28,000. Nelson Roberts Investment Advisors LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $30,000. Finally, AlphaMark Advisors LLC boosted its stake in shares of Edwards Lifesciences by 281.8% during the 4th quarter. AlphaMark Advisors LLC now owns 210 shares of the medical research company’s stock worth $32,000 after acquiring an additional 155 shares in the last quarter. 84.87% of the stock is owned by institutional investors and hedge funds.

In related news, CEO Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock in a transaction on Thursday, January 3rd. The stock was sold at an average price of $143.90, for a total transaction of $4,719,920.00. Following the completion of the sale, the chief executive officer now owns 75,926 shares of the company’s stock, valued at $10,925,751.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Huimin Wang sold 4,000 shares of Edwards Lifesciences stock in a transaction on Friday, January 4th. The shares were sold at an average price of $145.33, for a total value of $581,320.00. Following the sale, the vice president now directly owns 35,224 shares of the company’s stock, valued at approximately $5,119,103.92. The disclosure for this sale can be found here. In the last ninety days, insiders sold 136,868 shares of company stock valued at $22,406,044. 1.84% of the stock is currently owned by insiders.

Shares of Edwards Lifesciences stock opened at $188.99 on Monday. The firm has a market capitalization of $39.27 billion, a PE ratio of 40.21, a price-to-earnings-growth ratio of 2.44 and a beta of 0.90. The company has a quick ratio of 1.92, a current ratio of 2.61 and a debt-to-equity ratio of 0.19. Edwards Lifesciences Corp has a 12 month low of $123.00 and a 12 month high of $197.86.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, January 31st. The medical research company reported $1.17 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.17. The business had revenue of $977.70 million during the quarter, compared to analysts’ expectations of $973.72 million. Edwards Lifesciences had a return on equity of 31.09% and a net margin of 19.40%. During the same quarter last year, the firm posted $0.94 earnings per share. As a group, analysts predict that Edwards Lifesciences Corp will post 5.21 earnings per share for the current fiscal year.

Several research firms have recently weighed in on EW. Raymond James raised their price objective on Edwards Lifesciences from $160.00 to $175.00 and gave the stock an “outperform” rating in a research note on Thursday, December 6th. Citigroup raised their price objective on Edwards Lifesciences from $118.00 to $119.00 and gave the stock a “sell” rating in a research note on Wednesday, January 2nd. Morgan Stanley raised their price objective on Edwards Lifesciences from $157.00 to $180.00 and gave the stock an “overweight” rating in a research note on Friday, December 7th. BMO Capital Markets raised their price objective on Edwards Lifesciences to $204.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, Canaccord Genuity raised their price objective on Edwards Lifesciences from $177.00 to $186.00 and gave the stock a “positive” rating in a research note on Wednesday, January 16th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company. Edwards Lifesciences presently has a consensus rating of “Buy” and an average price target of $178.00.

COPYRIGHT VIOLATION NOTICE: This report was published by WKRB News and is the sole property of of WKRB News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.wkrb13.com/2019/03/25/grace-capital-trims-stake-in-edwards-lifesciences-corp-ew.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Recommended Story: Why are analyst ratings important in trading stocks?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.